LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Evolveimmune Therapeutics Inc.
Headquarters:
Branford, CT, United States
Website:
https://www.evolveimmune.com/...
Year Founded:
2020
Status:
Private
BioCentury
|
Nov 5, 2024
Deals
Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist
Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers
Read More
BioCentury
|
Dec 14, 2023
Deals
Dec. 13 Quick Takes: Vertex heads off patent issues with Editas deal
Plus: Pfizer loses $11B in value after 2024 guidance and updates from J&J, Shattuck Labs, Vir, CARsgen, Freya and EvolveImmune
Read More
BioCentury
|
Nov 10, 2023
Product Development
Costimulatory bispecifics bring new biology to T cell engagers
Abstracts at SICT, ASH describe T cell engagers targeting alternative receptors on the immune cells
Read More
BioCentury
|
Jul 8, 2022
Management Tracks
BI’s Fine becomes president of R&D at EvolveImmune
Plus Sallah joins Genespire as CMO, and updates from Kinaset, Andera, Ariceum and more
Read More
Items per page:
10
1 - 4 of 4